Physcion-Loaded, Folic Acid-Conjugated DSPE-PEG Liposomes for Targeted Therapy of Ulcerative Colitis

Conventional therapeutic agents for ulcerative colitis (UC) exhibit limited efficacy and toxic side effects. Although the natural compound physcion (PHY) demonstrates multi-target anti-inflammatory potential, its clinical application is constrained by poor water solubility and insufficient targeting capability. To address this, we developed folate receptor (FR)-targeted DSPE-PEG liposomes to encapsulate PHY and enhance colonic delivery efficiency. The formulation was prepared using the thin-film hydration method and optimised by central composite design. The resulting liposomes exhibited uniform particle size (PS) (approximately 160 nm, polydispersity index [PDI] < 0.18), high entrapment efficiency (EE, >92%), and excellent stability under storage conditions. In vitro release experiments revealed that the targeted liposomes significantly improved PHY release efficiency. Cellular uptake studies demonstrated enhanced uptake of the FA-modified liposomes in inflammatory EC cells, with the findings being consistent with FR-associated uptake. Pharmacokinetic studies demonstrated that liposomal formulation markedly prolonged the drug half-life and enhanced bioavailability. Tissue distribution experiments further validated its colon-specific enrichment capacity. In a dextran sulfate sodium (DSS)-induced UC mouse model, the targeted liposomes significantly repaired colonic mucosal structure and reduced fibrotic deposition. The treatment inhibited release of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) and alleviated oxidative stress, which is consistent with coordinated regulation of NF-κB/Nrf2-associated inflammatory and antioxidant responses. The therapeutic efficacy surpassed that of conventional liposomes and positive control drugs. Safety assessments indicated no significant cytotoxicity toward normal cells. This study provides an effective targeted drug delivery system to overcome limited clinical applications of PHY and establishes a theoretical and technological foundation for FR-targeted delivery strategies in UC.

Authors

Institutions

Publication Details

Journal
Journal of drug targeting
Published
2026-06-24
DOI
https://doi.org/10.1080/1061186x.2026.2694521
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Physcion-Loaded, Folic Acid-Conjugated DSPE-PEG Liposomes for Targeted Therapy of Ulcerative Colitis

Zhenhua Guan, Xuyang Liang, M T Li, Xueliang Li et al.
Journal of drug targeting
Inflammatory Bowel Disease
article

Physcion-Loaded, Folic Acid-Conjugated DSPE-PEG Liposomes for Targeted Therapy of Ulcerative Colitis

Zhenhua Guan, Xuyang Liang, M T Li, Xueliang Li, Jing Chen, Yi Xu
article en

Abstract

Conventional therapeutic agents for ulcerative colitis (UC) exhibit limited efficacy and toxic side effects. Although the natural compound physcion (PHY) demonstrates multi-target anti-inflammatory potential, its clinical application is constrained by poor water solubility and insufficient targeting capability. To address this, we developed folate receptor (FR)-targeted DSPE-PEG liposomes to encapsulate PHY and enhance colonic delivery efficiency. The formulation was prepared using the thin-film hydration method and optimised by central composite design. The resulting liposomes exhibited uniform particle size (PS) (approximately 160 nm, polydispersity index [PDI] < 0.18), high entrapment efficiency (EE, >92%), and excellent stability under storage conditions. In vitro release experiments revealed that the targeted liposomes significantly improved PHY release efficiency. Cellular uptake studies demonstrated enhanced uptake of the FA-modified liposomes in inflammatory EC cells, with the findings being consistent with FR-associated uptake. Pharmacokinetic studies demonstrated that liposomal formulation markedly prolonged the drug half-life and enhanced bioavailability. Tissue distribution experiments further validated its colon-specific enrichment capacity. In a dextran sulfate sodium (DSS)-induced UC mouse model, the targeted liposomes significantly repaired colonic mucosal structure and reduced fibrotic deposition. The treatment inhibited release of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) and alleviated oxidative stress, which is consistent with coordinated regulation of NF-κB/Nrf2-associated inflammatory and antioxidant responses. The therapeutic efficacy surpassed that of conventional liposomes and positive control drugs. Safety assessments indicated no significant cytotoxicity toward normal cells. This study provides an effective targeted drug delivery system to overcome limited clinical applications of PHY and establishes a theoretical and technological foundation for FR-targeted delivery strategies in UC.

Journal of drug targeting
The First People’s Hospital of Lianyungang (CN), Nanjing Medical University (CN)
Openalex Percentile: Top 7%
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.